Amgen, Allergan Claim Biosimilar is Clinically Equivalent to Avastin

Amgen and Allergan claim their biosimilar candidate is clinically equivalent to Roche’s blockbuster Avastin in adult patients with advanced non-small cell lung cancer.

The companies announced results of a Phase 3 study involving 642 patients showed ABP 215 is comparable to Avastin (bevacizumab) for safety. They have not filed a BLA with the FDA, and have not disclosed filing dates, spokeswoman Kristen Davis said.  

In December 2011, Amgen and Allergan (then known as Watson) formed a collaboration to develop and commercialize on a worldwide basis four oncology antibody biosimilar medicines. — Jonathon Shacat